Treatment of dysfunctional uterine bleeding in the perimenopause: the effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment--a randomized, placebo-controlled, double-blind trial

Henk R. Franke, H. Franke, F. Froukje Snaaijer, Paul W. H. Houben, Marius J. van der Mooren
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2006 · vol. 22(12) , pp. 692–697 · doi:10.1080/09513590601015101 · PMID:17162712 · W2018949829
RCT OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Adding combined estradiol/norethisterone acetate to goserelin acetate for dysfunctional uterine bleeding in perimenopausal women prevented bone mineral density loss and improved climacteric complaints without adverse effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To assess the effects of adding combined estradiol/norethisterone acetate therapy (CENT) to goserelin acetate treatment (GA) of dysfunctional uterine bleeding (DUB) in perimenopausal women. METHODS: In a randomized, placebo-controlled, double-blind trial followed by an open follow-up study, 31 perimenopausal women with DUB were recruited from gynecological outpatient departments of two Dutch hospitals and randomized for treatment with either GA/placebo or GA/CENT for 6 months followed by 18 months of GA/CENT for all. The main outcome measures were abdominal pain, number of bleeding days, double-layer endometrial thickness (DET), Greene climacteric score (GCS), visual analog scale for well-being, bone mineral density (BMD) and mammographic density (BI-RAD score). RESULTS: Abdominal pain, number of bleeding days and DET decreased in both groups, the between-group difference in decrease not being statistically significant. GCS initially showed significant improvement in the GA/CENT group. BMD decreased significantly in the GA/placebo group (-4.1%) compared with the GA/CENT group (-0.3%). Another 18 months of GA/CENT did not result in a lasting difference in BMD between groups. BI-RAD scores did not differ significantly between or within the two groups. CONCLUSIONS: Adding CENT to GA treatment for DUB in perimenopausal women initially prevented BMD loss and improved climacteric complaints, while having no negative impact on vaginal bleeding, abdominal pain or BI-RAD scores. However, prolonged treatment did not result in a lasting prevention of bone loss.

My notes (saved in your browser only)

MeSH descriptors

Antineoplastic Agents, Hormonal Estradiol Goserelin Hormone Replacement Therapy Metrorrhagia Norethindrone Antineoplastic Agents, Hormonal Bone Density Bone Density Climacteric Climacteric Climacteric Double-Blind Method Drug Combinations Estradiol Female Goserelin Humans Mammography Metrorrhagia

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (42)

Cited by (1)

Source provenance

crossref
last seen: 2026-06-12T06:26:22.529813+00:00
openalex
last seen: 2026-05-11T06:01:13.017405+00:00
pubmed
last seen: 2026-10-08T21:04:05.892929+00:00
unpaywall
last seen: 2026-10-12T06:33:14.382917+00:00
License: CC0 · commercial use OK